Lymphoma, Small Lymphocytic Clinical Trial
Official title:
A Phase I Trial of BBR 2778 in Combination With Fludarabine, Dexamethasone and Rituximab in the Treatment of Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma
The aim of this trial is to determine the appropriate dose of pixantrone to be used in this combination and obtain data on the combination's safety and activity profile.
The FND-R regimen is commonly used in the treatment of indolent Non-Hodgkin's lymphoma (NHL)
and contains the chemotherapy agents mitoxantrone, fludarabine, dexamethasone (a steroid)
and the monoclonal antibody rituximab. In this trial we are replacing mitoxantrone with
pixantrone, an agent with a similar chemical structure (both agents are DNA intercalators).
The trial is being run in patients with relapsed or refractory indolent NHL and aims to
define the appropriate dose of pixantrone to be used in this combination, as well as to
obtain data on pixantrone's safety and activity profile in combination with these drugs.
This trial is expected to recruit up to 30 patients in the USA. Patients will be treated
with the drug combination for up to eight months and then followed closely in the four-week
period after the last administration. After that, patients will receive physician check-ups
every three months.
;
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Withdrawn |
NCT02677948 -
Multicenter Study of Pacritinib Combined With Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03331198 -
Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
|
Phase 1/Phase 2 | |
| Recruiting |
NCT02991638 -
Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers
|
Phase 3 | |
| Terminated |
NCT00083473 -
A Pilot Study of Pivanex in Patients With Chronic Lymphocytic Leukemia
|
Phase 2 | |
| Terminated |
NCT00290407 -
Rituximab Plus Beta-Glucan in Chronic Lymphocytic Leukemia(CLL)/Small Lymphocytic Lymphoma (SLL)
|
Phase 2 | |
| Completed |
NCT00081809 -
A Safety and Effectiveness Study of Vaccine Therapy in Patients With Indolent Lymphoma
|
Phase 2 | |
| Terminated |
NCT01005979 -
A Phase I Trial Using Cyclophosphamide, Rituximab and Revlimid (CR2) for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Small Lymphocytic Lymphoma (SLL)
|
Phase 1 | |
| Completed |
NCT00783367 -
Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas
|
Phase 2 | |
| Completed |
NCT00546793 -
Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL
|
Phase 1/Phase 2 | |
| Completed |
NCT04626843 -
Intermittent Fasting and CLL/SLL
|
Phase 1 | |
| Terminated |
NCT02292225 -
Duvelisib With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi (SYNCHRONY)
|
Phase 1 | |
| Terminated |
NCT00636155 -
EL625 in Persistent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
|
Phase 2 | |
| Recruiting |
NCT03375619 -
Long-term Follow-up Study of Patients Receiving CAR-T Cells
|
||
| Recruiting |
NCT05947851 -
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010)
|
Phase 3 | |
| Active, not recruiting |
NCT01181271 -
Tandem Auto-Allo Transplant for Lymphoma
|
Phase 2 | |
| Completed |
NCT00143065 -
Fludarabine, Rituximab, and Alemtuzumab for B-Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
|
Phase 2 | |
| Terminated |
NCT04342117 -
Observational Trial of Real-World Treatment Utilization and Effectiveness of PI3K-inhibitors in CLL/SLL and FL
|